We are requesting funds for a research career development program in Pediatric and Medical Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. The Career Development Program will interface with our Pediatric and Medical Oncology Research Training Programs at the Fred Hutchinson Cancer Research Center (FHCRC) and the Departments of Pediatrics and Medicine at the University of Washington (UW) with the goal of developing clinical investigators. It will support physicians who have completed three years of fellowship training in the pediatric or medical oncology training programs. Prior to entry into the program, fellows will have acquired clinical skills and basic laboratory tools of modern biology. Those most qualified and motivated to enter into investigative endeavors in clinical research will be selected. During their two to three years supported by the career development program, trainees will gain the tools and experience necessary to conduct clinical research, translate their findings to patients, and generate sufficient data to help establish independent research careers.
The aim of their projects will be to contribute new and useful information relevant to clinical oncology and to develop the clinical research capabilities of the trainees. Clinical research projects in the areas of bone marrow transplantation, immunology and immunotherapy, transplantation biology, normal and malignant hematopoiesis, human immunogenetics, neurooncology, molecular biology, and gene therapy, as well as other programs, will be used for training. Trainees will also gain experience in clinical protocol development, conduct, and evaluation, and will receive didactic training, in biostatistics, clinical trial design and biomedical research integrity. This program involves the laboratory and clinical research facilities of the Fred Hutchinson Cancer Research Center and the University of Washington, and the clinical facilities of the Seattle Cancer Care Alliance and the Division of Hematology-Oncology at the Children's Hospital and Regional Medical Center, the primary clinical pediatric service of the University of Washington.
The aim of the Pediatric and Medical Oncology Career Development Program is to provide physicians with the tools and experience necessary to conduct clinical research, translate their findings to patients, and generate sufficient data to help establish independent research careers. Trainees will contribute new and useful information relevant to clinical oncology.
|Veatch, Joshua R; Lee, Sylvia M; Fitzgibbon, Matthew et al. (2018) Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest 128:1563-1568|
|Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659|
|Chapuis, Aude G; Lee, Sylvia M; Thompson, John A et al. (2016) Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 213:1133-9|
|Salit, Rachel B; Milano, Filippo; Delaney, Colleen (2016) Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation. Biol Blood Marrow Transplant 22:339-343|
|Rosinski, Steven Lawrence; Stone, Brad; Graves, Scott S et al. (2016) Minor Antigen Vaccine-Sensitized DLI: In Vitro Responses Do Not Predict In Vivo Effects. Transplant Direct 2:e71|
|Chapuis, Aude G; Roberts, Ilana M; Thompson, John A et al. (2016) T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol 34:3787-3795|
|Cassaday, Ryan D; Stevenson, Philip A; Gooley, Theodore A et al. (2015) High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol 171:788-97|
|Cassaday, Ryan D; Goy, Andre; Advani, Suresh et al. (2015) A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 15:392-7|
|Dahlberg, A; Woo, S; Delaney, C et al. (2015) Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity. Leukemia 29:1948-51|
|Hadland, Brandon K; Varnum-Finney, Barbara; Poulos, Michael G et al. (2015) Endothelium and NOTCH specify and amplify aorta-gonad-mesonephros-derived hematopoietic stem cells. J Clin Invest 125:2032-45|
Showing the most recent 10 out of 53 publications